ABSTRACT
Despite progress made with immune checkpoint inhibitors and targeted therapies, skin cancer remains a significant public health concern in the United States. The intricacies of the disease, encompassing genetics, immune responses, and external factors, call for a comprehensive approach. Techniques in systems genetics, including transcriptional correlation analysis, functional pathway enrichment analysis, and protein-protein interaction network analysis, prove valuable in deciphering intricate molecular mechanisms and identifying potential diagnostic and therapeutic targets for skin cancer. Recent studies demonstrate the efficacy of these techniques in uncovering molecular processes and pinpointing diagnostic markers for various skin cancer types, highlighting the potential of systems genetics in advancing innovative therapies. While certain limitations exist, such as generalizability and contextualization of external factors, the ongoing progress in AI technologies provides hope in overcoming these challenges. By providing protocols and a practical example involving Braf, we aim to inspire early-career experimental dermatologists to adopt these tools and seamlessly integrate these techniques into their skin cancer research, positioning them at the forefront of innovative approaches in combating this devastating disease.
Subject(s)
Skin Neoplasms , Humans , Skin Neoplasms/genetics , SkinABSTRACT
BACKGROUND: The innate immune system is recognized as an essential aspect of COVID-19 pathogenesis. Toll-like receptors (TLRs) are important in inducing antiviral response, triggering downstream production of interferons (IFNs). Certain loss-of-function variants in TLR7 are associated with increased COVID-19 disease severity, and imiquimod (ImiQ) is known to have immunomodulating effects as an agonist of TLR7. Given that topical imiquimod (topImiQ) is indicated for various dermatologic conditions, it is necessary for dermatologists to understand the interplay between innate immunity mechanisms and the potential role of ImiQ in COVID-19, with a particular focus on TLR7. SUMMARY: Our objective was to survey recent peer-reviewed scientific literature in the PubMed database, examine relevant evidence, and elucidate the relationships between IFNs, TLR7, the innate immune system, and topImiQ in the context of COVID-19. Despite limited studies on this topic, current evidence supports the critical role of TLRs in mounting a strong immune response against COVID-19. Of particular interest to dermatologists, topImiQ can result in systemic upregulation of the immune system via activation of TLR7. Key Message: Given the role of TLR7 in the systemic activation of the immune system, ImiQ, as a ligand of the TLR7 receptor, may have potential therapeutic benefit as a topical immunomodulatory treatment for COVID-19.
Subject(s)
COVID-19/prevention & control , Imiquimod/administration & dosage , Immunity, Innate , Interferons/administration & dosage , SARS-CoV-2 , Toll-Like Receptor 7/metabolism , Up-Regulation/drug effects , Adjuvants, Immunologic/pharmacology , Administration, Topical , Animals , Antiviral Agents/administration & dosage , COVID-19/epidemiology , COVID-19/metabolism , HumansSubject(s)
Suture Techniques , Sutures , Dermatologic Surgical Procedures , Humans , Skin , Surgical Wound InfectionSubject(s)
Bowen's Disease , Skin Diseases , Skin Neoplasms , Bowen's Disease/therapy , Humans , Skin Neoplasms/therapySubject(s)
Epidermolysis Bullosa Acquisita , Epidermolysis Bullosa , Pemphigoid, Benign Mucous Membrane , Pemphigoid, Bullous , Basement Membrane , Epidermolysis Bullosa Acquisita/diagnosis , Epidermolysis Bullosa Acquisita/drug therapy , Humans , Immunosuppressive Agents , Mucous Membrane , Pemphigoid, Benign Mucous Membrane/drug therapySubject(s)
Emollients , Hygiene , Humans , Aged , Emollients/therapeutic use , Skin Care , HospitalsSubject(s)
Carcinoma, Basal Cell , Skin Neoplasms , Carcinoma, Basal Cell/surgery , Humans , Mohs Surgery , Skin Neoplasms/surgeryABSTRACT
This study underscores the persistent underrepresentation of women in academic dermatology leadership positions by examining the gender composition of editorial boards across top dermatology journals, emphasizing the urgent need for proactive strategies to promote diversity, equity, and inclusion.